Arch Therapeutics 5/23/2023 Earnings Report

Arch Therapeutics EPS Results

• Actual EPS: $0.21
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Arch Therapeutics Revenue Results

• Actual Revenue: $0.02 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Arch Therapeutics Announcement Details

• Date: 5/23/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Arch Therapeutics (OTCMKTS:ARTH) (OTCMKTS: ARTH) is a development‐stage medical device company focused on applying its proprietary synthetic self‐assembling peptide technology to hemostasis, sealant and antimicrobial applications. Its platform is designed to rapidly form protective barriers in wet surgical and trauma environments without requiring external energy, with the goal of improving patient outcomes and reducing procedure times.

The company’s lead product candidates utilize its AC5™ formulation, which is being evaluated for a range of clinical indications including bleeding control during open and minimally invasive surgeries, emergency trauma care and interventional radiology procedures. Arch is also exploring advanced applications of its peptide technology in tissue regeneration and infection prevention.

Headquartered in Framingham, Massachusetts, the company primarily operates within the United States while pursuing regulatory approvals in key international markets. Arch collaborates with clinical partners and contract manufacturers to advance its pipeline through preclinical and clinical studies, as well as to scale for potential commercialization.

Established in the late 2000s, Arch has evolved from a research‐driven enterprise to a product development organization. Its leadership team comprises professionals with backgrounds in medical device engineering, clinical research and regulatory affairs, positioning the company to navigate the complexities of developing next‐generation surgical and trauma care solutions.